Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Stanford researchers test drug to fight depression faster in elderly

17.10.2002


Elderly people who suffer from depression can take the edge off faster by using a drug called mirtazapine, which appears to work more quickly compared to rival drugs. These results come from a study by researchers at Stanford University Medical Center who compared two drugs in an eight-week trial. Although both drugs treated the depression, mirtazapine began working sooner and eased the patient’s anxiety - a common effect of depression in elderly people.



"There’s a sense that we need something else for elderly patients and here is an alternative that is well tolerated," said Alan Schatzberg, MD, the Kenneth T. Norris, Jr. Professor of Psychiatry and Behavioral Sciences. "It gives doctors an alternative."

Anti-depression drugs come in two common varieties. Selective serotonin reuptake inhibitors (SSRIs), such as the popular Zoloft and Prozac, cause the brain chemical serotonin to linger in the gaps between neurons. These drugs are extremely effective but can interact with other drugs such as beta-blockers, which many elderly people take to quell heart problems.


The alternative to SSRIs - tricyclic antidepressants (TCAs) - can have side effects that make them less appealing. However, mirtazapine, a non-tricyclic that works similarly to TCA’s, has few side effects or drug interactions. "Mirtazapine has TCA-like properties without the side effects," Schatzberg said. "A lot of people use it where they might have used a TCA, particularly in the elderly." Mirtazapine enhances the effects of serotonin and other brain chemicals and also acts as a mild sedative.

Schatzberg tested mirtazapine’s effectiveness against paroxetine (sold under the name Paxil), a popular SSRI. In his trial, 255 depressed people 65 or older were randomly divided into groups taking either mirtazapine or paroxetine. Psychiatrists analyzed the patients’ depression throughout an eight-week test period.

Although the drugs were equally effective by the end of the eight-week period, depression in patients on mirtazapine had eased significantly by day 14 compared with people taking paroxetine. Those patients also had less anxiety and an easier time sleeping. In addition, those who took mirtazapine had fewer side effects such as nausea, tremors or flatulence - side effects that caused 26 percent of those taking paroxetine to discontinue the trial compared with 15 percent of those on mirtazapine. During an extended eight-week phase after the initial trial, the two drugs remained equally effective.

Schatzberg said mirtazapine is also effective more quickly than SSRIs in younger people; however younger people are less likely to stay on the drug because it can cause some weight gain and grogginess. "Weight gain is a problem for younger patients," Schatzberg said. "There’s less initiative to use the drug in these people."

These side effects that drive younger patients away can be a boon to the elderly who are less concerned about their weight but who suffer from anxiety and insomnia. "Depressed people who are older often have agitation," Schatzberg said. "Mirtazapine calmed these patients and helped them sleep, especially early on."

Schatzberg said that many doctors already use mirtazapine to treat depression in their elderly patients in order to avoid the drug interactions that are common with SSRIs. "But it certainly hasn’t saturated the market in the elderly," he noted.


Stanford University Medical Center integrates research, medical education and patient care at its three institutions - Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital at Stanford. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Amy Adams | EurekAlert!
Further information:
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht Nanoparticles as a Solution against Antibiotic Resistance?
15.12.2017 | Friedrich-Schiller-Universität Jena

nachricht Plasmonic biosensors enable development of new easy-to-use health tests
14.12.2017 | Aalto University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: First-of-its-kind chemical oscillator offers new level of molecular control

DNA molecules that follow specific instructions could offer more precise molecular control of synthetic chemical systems, a discovery that opens the door for engineers to create molecular machines with new and complex behaviors.

Researchers have created chemical amplifiers and a chemical oscillator using a systematic method that has the potential to embed sophisticated circuit...

Im Focus: Long-lived storage of a photonic qubit for worldwide teleportation

MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.

Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...

Im Focus: Electromagnetic water cloak eliminates drag and wake

Detailed calculations show water cloaks are feasible with today's technology

Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...

Im Focus: Scientists channel graphene to understand filtration and ion transport into cells

Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.

To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...

Im Focus: Towards data storage at the single molecule level

The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.

Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

See, understand and experience the work of the future

11.12.2017 | Event News

Innovative strategies to tackle parasitic worms

08.12.2017 | Event News

AKL’18: The opportunities and challenges of digitalization in the laser industry

07.12.2017 | Event News

 
Latest News

Engineers program tiny robots to move, think like insects

15.12.2017 | Power and Electrical Engineering

One in 5 materials chemistry papers may be wrong, study suggests

15.12.2017 | Materials Sciences

New antbird species discovered in Peru by LSU ornithologists

15.12.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>